The Viral Vector Manufacturing Facility Pty Ltd (VVMF) Board is delighted to announce the appointment of Mr. Stephen Thompson as the inaugural Chief Executive Officer (CEO) of the Company, effective 1st July 2024.
Mr Thompson brings extensive leadership and management experience to VVMF with a strong global track record in Enterprise Leadership, Manufacturing and Operations, Commercial, Business Development and Alliance Partnerships, in market leading multinational companies including Baxter International Inc, Icon Group, Nestlé, Pacific Dunlop, and Proctor & Gamble.
Having obtained a 1st class Bachelor of Engineering (Chemical) (Hons) degree from UNSW, Sydney, Australia and working across both multinationals and the Ingham Institute for Applied Medical Research, Stephen is very well equipped to lead VVMF as the first CEO.
Stephen has a passion for developing high performing teams to ensure organisations deliver successfully.
Sue MacLeman, VVMF Chair and Non-Executive Director, said “We are absolutely delighted to have Stephen join us as our inaugural CEO. He brings a depth, breadth and diversity of experience to VVMF as it establishes itself as a commercial for-profit entity and the first viral vector manufacturing facility in Australia.”
“He brings a depth, breadth and diversity of experience to VVMF as it establishes itself as a commercial for-profit entity and the first viral vector manufacturing facility in Australia.”
— Sue MacLeman, VVMF Chair and Non-Executive Director
Mr Thompson said “I am honoured and excited to be part of this very important commercial initiative which will provide local manufacturing of advanced therapeutics using viral vector technology for patients in Australia, the Asia Pacific Region and globally, as we scale up the VVMF capabilities over the next few years.
Australia has a thriving research and development community, access to a diverse and educated workforce, and world renowned advance therapeutic expertise. I’m confident that VVMF will quickly become an important and respected member of this ecosystem.”
This announcement has been authorised by the Board of Directors of Viral Vector Manufacturing Facility Pty Ltd.